AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27283779
Drug: Sacubitril/valsartan (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (lower doses: 100/50/0 mg)
Trial: 27283779
Drug: Enalapril (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (lower doses: 5/2.5/0 mg)
Trial: 27283779
Drug: Any dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any dose reduction (both treatments)
Trial: 20649630
Drug: Glimepiride (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (up to 6 mg/day)
Trial: 11176977
Drug: Low-dose external
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose external beam irradiation at a dose of 14 Gy in 7 fractions of 2 Gy
Trial: 7875272
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 125 micrograms carbachol
Trial: 31905341
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg daily dose)
Trial: 31905341
Drug: Nonusers (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonusers (no aspirin)
Trial: 29432808
Drug: naloxegol 25
RxNorm normalized name: naloxegol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxegol 25 mg once daily
Trial: 26911949
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg daily orally for at least 15 days
Trial: 20730091
Drug: Meningococcal serogroup
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal serogroup C conjugate vaccine (MenCC) administered at 14 months of age and catch-up immunization for ages 14 months to 18 years.
Trial: 20730091
Drug: Meningococcal serogroup
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal serogroup C conjugate vaccine (MenCC) administered above 5 years of age.
Trial: 10807465
Drug: Immunoadsorption (IA)
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoadsorption (IA) and subsequent immunoglobulin G (IgG) substitution
Trial: 10807465
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical treatment (Control group)
Trial: 1591948
Drug: Allopurinol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (50 mg by mouth 4 times a day)
Trial: 1591948
Drug: DMSO (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSO (500 mg by mouth 4 times a day)
Trial: 27173469
Drug: RVX-208 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVX-208 (100 mg b.i.d. for 29-33 days)
Trial: 24815101
Drug: Progestin‐only pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin‐only pills (POPs)
Trial: 16281834
Drug: Oral ciprofloxacine
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacine (0.5 g) 90‐120 min before TUR
Trial: 16281834
Drug: Intravenous ciprofloxacine
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ciprofloxacine (0.4 g) 30‐60 min before TUR
Trial: 16281834
Drug: Routine antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antibiotic prophylaxis (control)
Trial: 10461844
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g cefuroxime administered intravenously 10 min before surgery
Trial: 8594657
Drug: Lobenzarit disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lobenzarit disodium (CCA) in combination with sodium aurothiomalate and D-penicillamine (group-A)
Trial: 7369913
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg cefaclor
Trial: 23252444
Drug: High-frequency physical
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency physical therapy
Trial: 14701778
Drug: Motexafin gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motexafin gadolinium (MGd) 5 mg/kg/d with whole-brain radiation therapy (WBRT) 30 Gy in 10 fractions
Trial: 14701778
Drug: Whole-brain radiation
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-brain radiation therapy (WBRT) 30 Gy in 10 fractions without motexafin gadolinium (MGd)
Trial: 9180238
Drug: Lipid-modulating therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-modulating therapy that lowers LDL cholesterol
Trial: 9180238
Drug: Lipid-modulating therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-modulating therapy that lowers LDL cholesterol and decreases serum triglyceride and/or increases HDL cholesterol
Trial: 27999883
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg in pediatric subjects
Trial: 27999883
Drug: Alogliptin 12.5
RxNorm normalized name: alogliptin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5 mg in pediatric subjects
Trial: 27999883
Drug: Alogliptin 25
RxNorm normalized name: alogliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg in adults
Trial: 16571278
Drug: Jiawei Huangqi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiawei Huangqi Guizhi Wuwu Decoction (JHGWD) combined with chemotherapy and oxaliplatin
Trial: 11144398
Drug: Cefdinir 14
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 14 mg/kg daily (QD)
Trial: 11144398
Drug: Cefdinir 7
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir 7 mg/kg twice a day (BID)
Trial: 11144398
Drug: Amoxicillin/clavulanate 40/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate 40/10 mg/kg/day divided TID
Trial: 9225366
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human Interleukin‐3 (rhIL‐3) at doses of 0.5, 1.0, 5.0, 7.5, and 10 micrograms/kg
Trial: 9225366
Drug: Control cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control cycles (no cytokine therapy)
Trial: 9225366
Drug: Cytokine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokine treatment (rhIL‐3 and rhGM‐CSF)
Trial: 8452175
Drug: Fleroxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (400 mg once a day)
Trial: 8452175
Drug: Ceftazidime (0.5‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (0.5‐2 g three times a day or 1‐2 g twice a day)
Trial: 3732047
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy in initial treatment
Trial: 25885678
Drug: Unused returned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unused returned medication
Trial: 25885678
Drug: Plasma nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma nevirapine concentration >100 ng/ml
Trial: 25885678
Drug: Missed doses
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Missed doses by maternal verbal reports
Trial: 20809267
Drug: Selenium-enriched chicken
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium-enriched chicken (4 portions of 200 g/week)
Trial: 20809267
Drug: Non-enriched chicken
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-enriched chicken (4 portions of 200 g/week)
Trial: 17717532
Drug: Sulfurous mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfurous mineral water (500 ml day(‐1) for 2 weeks)
Trial: 11419888
Drug: Abciximab bolus
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab bolus plus 12-h infusion
Trial: 26200146
Drug: 2% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% CHX solution for 60 s after acid etching and before adhesive application
Trial: 23637033
Drug: Catheter-over-needle group
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter-over-needle group (received a second bolus of 20 mL of 0.2% ropivacaine postoperatively)
Trial: 23637033
Drug: Single-shot group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-shot group (received 25-30 mL of 1.5% lidocaine and 0.125% bupivacaine)
Trial: 21269402
Drug: Testosterone pellets
RxNorm normalized name: testosterone pellets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone pellets (75 mg each, 8 to 12 pellets, total 450 mg to 900 mg)
Trial: 18563471
Drug: Reboxetine (4-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (4-6 mg/d)
Trial: 18563471
Drug: Methylphenidate (20-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (20-50 mg/d)
Trial: 17586417
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg/HCTZ 12.5 mg
Trial: 17586417
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 mg/HCTZ 12.5 mg
Trial: 17586417
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg/HCTZ (stage 2 hypertension)
Trial: 17586417
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 mg/HCTZ (stage 2 hypertension)
Trial: 17586417
Drug: Valsartan 320
RxNorm normalized name: valsartan 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 320 mg/HCTZ (stage 1 hypertension)
Trial: 15556954
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (manipulation followed by exercise)
Trial: 11162286
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with indomethacin
Trial: 7900078
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) 5000 IU
Trial: 7900078
Drug: Enoxaparin 1
RxNorm normalized name: ENOXAPARIN 100MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg body weight (mean 75 mg)
Trial: 7900078
Drug: Enoxaparin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (high dose)
Trial: 2839439
Drug: Concurrent Platinum
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Platinum (DDP) Etoposide (VP‐16) chemotherapy and twice‐daily, 150 cGy radiotherapy to a total dose of 4500 cGy in 3 weeks.
Trial: 21974760
Drug: Valsartan/HCTZ 160/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/HCTZ 160/12.5 mg, titrated to 320/25 mg at week 4
Trial: 21974760
Drug: Amlodipine/HCTZ (HCTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/HCTZ (HCTZ 12.5 mg monotherapy, then amlodipine 5 mg at week 8 and 10 mg at week 12)
Trial: 18381905
Drug: DMXB-A (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMXB-A (higher dose)
Trial: 18381905
Drug: DMXB-A (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMXB-A (first treatment arm)
Trial: 17532523
Drug: Resiquimod 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resiquimod 0.01 mg/kg
Trial: 17532523
Drug: Resiquimod 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resiquimod 0.02 mg/kg
Trial: 9450162
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (300 mg, Orfiril long) after fasting
Trial: 9450162
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (300 mg, Orfiril long) after a high energy high fat breakfast
Trial: 8192698
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg sustained-release theophylline (Bronchoretard) administered in a fasting state
Trial: 8192698
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg sustained-release theophylline (Bronchoretard) administered after a standard meal
Trial: 8192698
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg sustained-release theophylline (Bronchoretard) administered after a high-caloric fat evening meal
Trial: 30306604
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg l-selenomethionine daily for 6 months
Trial: 28114798
Drug: Intermittent metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent metoclopramide infusion (10 mg every 6 h)
Trial: 28114798
Drug: Continuous metoclopramide
RxNorm normalized name: metoclopramide Extended Release Oral Tablet [Gastrobid Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous metoclopramide infusion (2 mg/h)
Trial: 26541435
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 0.5 or 2.0 mg monthly or as needed
Trial: 24687826
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg per day for 10 weeks
Trial: 24687826
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg per day (4 weeks on, 2 weeks off, 4 weeks on) for 10 weeks
Trial: 23294071
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (500 mg)
Trial: 19297565
Drug: Annual screening
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual screening with PSA testing and digital rectal examination
Trial: 17968163
Drug: Observation (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (no further adjuvant treatment)
Trial: 9670578
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (Amoxycillin, Clarithromycin, Omeprazole) for 6 days
Trial: 9670578
Drug: Monotherapy (Omeprazole)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (Omeprazole) for 6 weeks
Trial: 9670578
Drug: Monotherapy (Omeprazole)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (Omeprazole)
Trial: 2452456
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g GVG per day for 3 months
Trial: 2452456
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g GVG per day for 3 months
Trial: 2452456
Drug: GVG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GVG treatment
Trial: 25843270
Drug: Licensed inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed inactivated trivalent influenza vaccine (IIV3)
Trial: 21059888
Drug: Apratastat (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apratastat (oral administration, single or multiple doses, twice daily)
Trial: 19350334
Drug: Knee Outcome
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knee Outcome Survey-Activities of Daily Living Scale (KOS-ADLS) questionnaire completed twice a week for test-retest reliability (Group 1)
Trial: 19350334
Drug: Knee Outcome
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knee Outcome Survey-Activities of Daily Living Scale (KOS-ADLS) questionnaire with additional tests for validity (Group 2)
Trial: 7902637
Drug: Vecuronium (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.04 mg.kg‐1)
Trial: 7902637
Drug: Atracurium (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.2 mg.kg‐1)
Trial: 3026106
Drug: RIT 4237
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIT 4237 vaccine alone
Trial: 3026106
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of polio and RIT 4237 vaccines
Trial: 24950747
Drug: GSK561679 (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK561679 (350 mg nightly for six weeks)
Trial: 10859040
Drug: Gavestinel (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gavestinel (800 mg loading dose followed by 200 mg every 12 h for five doses)
Trial: 1397742
Drug: Intravenous omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole, 40 mg i.v. bolus twice daily for up to 5 days
Trial: 1397742
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ranitidine, 400 mg daily for the same time period
Trial: 1397742
Drug: Intravenous omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole, 40 mg twice daily
Trial: 1397742
Drug: Intravenous omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole, 40 mg three times daily
Trial: 4010475
Drug: 14 gm
RxNorm normalized name: Coconut Oil 14 GM/1 DOSE Oral Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 gm choline and 0.35 mg scopolamine (Ch‐Sc)
Trial: 30395147
Drug: Eating as
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eating as Treatment (EAT)
Trial: 25758100
Drug: Type 2
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type 2 implant placement
Trial: 25758100
Drug: Both Type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Type 1 and Type 2 implant placements
Trial: 20412501
Drug: Fluoroscopically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopically guided caudal epidural steroid, local anesthetic, and hypertonic saline (group 1)
Trial: 20412501
Drug: Fluoroscopically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopically guided caudal epidural steroid, hypertonic saline, local anesthetic, and hyaluronidase (group 2)
Trial: 18157412
Drug: Control (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (subcutaneous insulin)
Trial: 9042093
Drug: Moderate beer
RxNorm normalized name: BEER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate beer consumption (330 mL/day, 20 g of alcohol) for 30 days
Trial: 7894522
Drug: BIA in
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA in combination with waist-to-hip ratios
Trial: 27534402
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection followed by 12‐h infusion (IV‐IV)
Trial: 27534402
Drug: Intracoronary bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary bolus injection followed by intravenous infusion (IC‐IV)
Trial: 27534402
Drug: Only intracoronary
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only intracoronary bolus injection (IC)
Trial: 27313412
Drug: TC 150
RxNorm normalized name: 3TC 150 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC 150 mg
Trial: 27313412
Drug: TC 300
RxNorm normalized name: 3TC 300 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC 300 mg
Trial: 27313412
Drug: TC 150
RxNorm normalized name: 3TC 150 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC 150 mg and TC 300 mg
Trial: 21289531
Drug: DTwP‐Hib, hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP‐Hib, hepatitis B, and OPV vaccines (Group 2)
Trial: 21289531
Drug: DTaP‐IPV‐Hep B‐PRP‐T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP‐IPV‐Hep B‐PRP‐T with hepatitis B vaccine at birth (Group 3)
Trial: 19814699
Drug: Alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg, once daily for 6 weeks
Trial: 19814699
Drug: Tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine ER 4 mg, once daily for 6 weeks